Answers are grounded in this paper and cite their sources.
Chinese Hamster Ovary (CHO) cells have long served as the primary workhorse of the biopharmaceutical industry. Conventional cell line development relies on random integration methods, which require multiple rounds of selection pressure and clonal verification to isolate monoclonal cell lines with the highest productivity. However, this approach often results in significant clonal variation and poor expression stability, thereby necessitating labor-intensive screening. To address the limitations mentioned above, site-specific integration of a protein expression cassette into predefined chromosomal loci exhibiting high expression and stability has emerged as a promising strategy. In this study, we established a high-throughput method for the detection and analysis of insertion sites to identify genomic “hotspot” loci from a stable, high-expression cell library generated via lentiviral random integration. Among 5,474 candidate integration loci, 12 candidate hotspot loci, together with four previously reported loci, were selected for validation of monoclonal antibody expression using a CRISPR/Cas9-mediated site-specific integration system. In parallel, we developed an Auto-MCS platform for CHO cell line development that enables the simultaneous screening of hundreds of monoclonal cells, thereby facilitating the efficient generation and characterization of site-specifically integrated monoclonal cell lines. Comparative evaluation of clones carrying different integration loci in 24-deep-well plates identified four newly discovered hotspots with 1.55- to 3.22-fold higher relative specific productivity than the previously reported reference locus NW_003626341.1. Shake-flask evaluation was subsequently performed on three clones from each of these four newly identified hotspots, and the best-performing clone was selected for inoculation-density optimization and further fed-batch evaluation. Following optimization, this clone achieved a mean antibody titer of 1.172 ± 0.019 g/L in a 3-L bioreactor fed-batch culture. Collectively, these findings provide a set of productive genomic hotspots for site-specific integration and may facilitate the development of high-performance CHO cell lines for biopharmaceutical manufacturing.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: